Sandoz Shuffles Management And Sets Out Restructuring Plans

As ‘Fantastic Progress’ On Biosimilars Drives Sales Growth Of Almost A Tenth In Q2

Sandoz has revealed senior management changes and details of a restructuring plan to drive efficiencies, as the firm unveiled positive results for the second quarter of 2024 that saw biosimilars continue to drive solid growth for the company.

Company structure, management layers
Sandoz is reducing layers and simplifying its organization • Source: Shutterstock

Sandoz has announced management changes that have seen the firm announce a new chief commercial officer and head of Europe, at the same time as the company revealed details of a restructuring plan that would “reduce layers across the organization and simplify our processes” to drive efficiencies.

Pierre Bourdage, Sandoz’s chief commercial officer, is “unfortunately stepping down from his role for personal health reasons,” the company disclosed....

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Leadership

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C5

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C4

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.